AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05633498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Book
Description: Self-help book describing advice to cope with shift work
Study NCT05633498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: Basic sleep hygiene advice on a piece of paper
Study NCT05648487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery
Description: 1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy.
Study NCT05654233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
Study NCT04692701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulvinar deep brain stimulation
Description: Stimulation of the medial pulvinar
Study NCT06385184 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Observational study with no intervention
Study NCT05084053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Study NCT05858255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Please see Arms description.
Study NCT06433297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS
Description: After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique.
Study NCT06433297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS
Description: After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique.
Study NCT04843579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given as 60 mg oral capsule
Study NCT04843579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given as 500 mg oral capsule
Study NCT04843579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given as 4 mg oral capsule
Study NCT04843579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given as 40 mg oral capsule
Study NCT06432114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Awareness Program (SAP)
Description: SAP is a new rehabilitation program for people with severe mental health problems. SAP aims to help the target group manage anxiety outburst and live an active life through sensory modulation techniques.
Study NCT06432114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Treatment as usual is standard psychiatric care for the target group.
Study NCT06432114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Treatment as usual is standard psychiatric care for the target group.
Study NCT05354713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805
Description: NVP-1805 (80/10/20.8mg)
Study NCT05354713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1805-R1 and NVP-1805-R2
Description: coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
Study NCT05543239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS)
Description: Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) works by stimulating the auricular branches of the vagus nerve (mainly distributed in the concha cavity and conchae) through electrical impulses.Electrodes were placed on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. Stimulation pulses (frequency 30 Hz, pulse width 300 us) were generated by TaVNS device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then descend within 15 seconds to the maximum tolerable amount without pain. Inform the subject that target stimulus has been reached, then stimulate for 30 minutes.
Study NCT05543239 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)
Description: Place electrodes on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. The same stimulation pulses (30 Hz frequency, 300 us pulse width) were generated by the same device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then ramps down to zero stimulus over 15 seconds. The subjects were told that the target stimulus has been reached. Patients receive sham stimulation for 30minutes.
Study NCT05875649 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: CLAG
Description: Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure
Study NCT06277505 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Take prebiotics and probiotics
Description: Take 3.5g prebiotic +2g prebiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
Study NCT06277505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle guidance
Description: lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
Study NCT06277505 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle guidance
Description: lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
Study NCT05677386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Primary preventive treatment guided by CTCA
Description: Computed tomography coronary angiography (CTCA)
Study NCT05677386 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cardiovascular risk Score
Description: Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
Study NCT06609031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic mucosal resection
Description: The SSLs less than 10mm in size in this group will be treated by EMR
Study NCT06609031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare polypectomy
Description: The SSLs less than 10mm in size in this group will be treated by CSP
Study NCT04706936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
Study NCT04706936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: 300mg/m2/d
Study NCT04706936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT06156553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PULSE school-based intervention
Description: PULSE - School-based intervention is a feasibility study designed to support active travel among adolescents. The curricular intervention is designed to increase the students' health literacy as well as their autonomous motivation for active travel. The intervention will last for 6 weeks during fall 2023. The first session will be delivered by a science and education center, and the consecutive sessions will be delivered by teachers. PULSE sessions will contribute to the attainment of specific competence aims related to two interdisciplinary topics, Health and life skills and Sustainability, as defined in PE, social science, and science. The research question is the following: Can increased attention to the barriers and benefits of active travel increase physical activity for youths?
Study NCT06359197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Pill
Description: Participants would take two Wake-Ups 200mg Caffeine tablets to meet the target dose of 400mg of caffeine. These are a registered natural health product with Health Canada (NPN 80003474). They are developed by Adrem Brands, which was established in 1951. Quality control testing is performed at a third-party independent lab, Nucro-Technics, which is audited by Health Canada and the US FDA. This ensures that the caffeine tablets comply with Health Canada standards. The tablets contain caffeine anhydrous-a processed, dehydrated form of caffeine-which allows for a standard dose per tablet. The tablets are sugar-free, which reduces the confounding effect of sugar on our results; thus, the investigators can be more confident that the obtained results are reflective of the association between caffeine and the CVD-related protein biomarkers.
Study NCT06359197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
Study NCT06359197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TASSO+ Device
Description: TASSO+ is a blood lancet device that uses negative pressure to draw capillary blood from the upper arm into a standard SST tube of volume 500μL. The small volume of blood collected makes this device less invasive than traditional collection methods. It is also safer and easier to use since it offers automated sample collection. TASSO manufactures a number of special devices for capillary blood sampling that have been validated as safe for consumer use, and the Tasso+ device is licensed with Health Canada for research use.
Study NCT06359197 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TASSO+ Device
Description: TASSO+ is a blood lancet device that uses negative pressure to draw capillary blood from the upper arm into a standard SST tube of volume 500μL. The small volume of blood collected makes this device less invasive than traditional collection methods. It is also safer and easier to use since it offers automated sample collection. TASSO manufactures a number of special devices for capillary blood sampling that have been validated as safe for consumer use, and the Tasso+ device is licensed with Health Canada for research use.
Study NCT06359197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finger prick and collection on Whatman Protein 903 Saver Cards
Description: The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.
Study NCT06297720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hydration
Description: * Researchers moisten the patient's throat with a wet cotton swab. If no nausea or vomiting occurs after five minutes, proceed to the next stage.~* Provide an ice cube of potable water for the patient to hold in their mouth. If no nausea or vomiting occurs after ten minutes, proceed to the next stage.~* Offer 10-20ml of potable water for the patient to drink under medical supervision. If no nausea or vomiting occurs and the patient requests more water, administer 10-20ml every ten minutes, assessing for any adverse effects each time. The total water intake should not exceed 500ml.
Study NCT04845399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Description: Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
Study NCT06378723 — intervention group
Intervention type: OTHER
Intervention: Balance Tests
Description: With the scales and tests the children trunk control, quality of upper extremity skills, single leg stance duration will be measured
Study NCT06359197 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Finger prick and collection on Whatman Protein 903 Saver Cards
Description: The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.
Study NCT06359197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Sampling
Description: Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
Study NCT06198270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Closed Kinetic Chain Exercise
Description: Closed chain exercise plan of 5 exercises, 10reps x 3sets of each, 3 days in a week for 4-weeks, all values measured before and after 4-weeks.
Study NCT06198270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training with K Tape
Description: Neuromuscular training plan of 5 exercises, 10reps x 3sets of each, 3 days in a week, for 4-weeks, all values measured before and after 4-weeks. Just After the session k-tape applied.
Study NCT04584671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
Study NCT04584671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity
Study NCT04584671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT
Study NCT04584671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test (6MWT)
Description: Participants will perform the six minute walk test as a measure of exercise capacity
Study NCT04584671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils
Study NCT04584671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.
Study NCT04584671 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
Study NCT04603742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
Study NCT04603742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
Study NCT05671354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the auto-wrapping commode chair
Description: The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
Study NCT06450236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 10 MG
Description: 1 tablet of Perampanel Tablets 10mg
Study NCT06450236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fycompa 10Mg Tablet
Description: 1 tablet of Perampanel Tablets 10mg
Study NCT05577325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group will be followed without health education
Description: After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.
Study NCT04676789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
Study NCT04676789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
Study NCT04676789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive intensity-modulated radiotherapy (IMRT)
Description: Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
Study NCT06359197 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Sampling
Description: Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
Study NCT05599347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill
Description: Tablet - 500 mg azithromycin (as dihydrate)
Study NCT05599347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
Study NCT05140252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast cancer decision aid
Description: The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
Study NCT05513755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardioneuroablation
Description: Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
Study NCT05182307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DurAVR™ THV System
Description: Transcatheter Aortic Valve Implantation (TAVI) Procedure